




The relative strengths and weaknesses of Acadia Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acadia Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 71% points. The greatest weakness of Acadia Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 47% points.

The company's Economic Capital Ratio, given in the ranking table, is 325%, being 50% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	617,823
Cost of Goods Sold	10,843
Intangible Assets	0
Liabilities, Current	96,068
Liabilities, Non-Current	63,160
Other Assets	74,252
Other Compr. Net Income	-228
Other Expenses	8,649
Other Liabilities	0
Other Net Income	-1,738
Other Revenues	484,145
Property and Equipment	8,047
Research and Development	239,415
Selling, General and Administrative Expense	396,028

Output Variable	Value in 1000 USD
Assets	700,122
Liabilities	159,228
Expenses	654,935
Revenues	484,145
Stockholders Equity	540,894
Net Income	-172,528
Comprehensive Net Income	-172,642
BaseVar	1,000,198
ECR before Limited Liability	234%
Economic Capital Ratio	325%